Navigating the Tableting Maze for BCS Class III and IV Drugs

Ever feel like BCS Class III and IV drugs are designed to test your patience?

These compounds dominate today’s pipelines—Class III with its high solubility but stubborn low permeability, and Class IV hitting you with poor performance on both fronts. The mission is straightforward: boost dissolution and absorption so the drug actually works. Tools like hot melt extrusion, micronization, and amorphous solid dispersions have become lifesavers for bioavailability.

But here’s the reality check—tableting these enhanced materials isn’t always smooth sailing. Compression can introduce surprises: capping, sticking, or inconsistent release. The key? Recognizing that formulation choices and compaction are deeply intertwined.

Why Formulation Drives the Show

Think of it this way: your bioavailability fix (extrusion, micronization, or dispersion) creates a new material with its own personality.

1. Hot melt extrusion melts everything into a uniform matrix—perfect for turning crystalline nightmares into amorphous wonders. For Class IV, it delivers massive solubility jumps. Yet the glassy extrudate can be brittle, risking lamination under pressure. For Class III, adding permeation enhancers helps, but you need to ensure the tablet doesn’t become too dense and slow release.
2. Micronization ramps up surface area for faster dissolution—a quick win for Class IV solubility woes. The downside? Those fine particles clump like crazy, wrecking flow and inviting segregation. Suddenly your tablet weights vary, and hardness scatters.
3. Amorphous solid dispersions lock the drug in a high-energy state for supersaturation. Great for dual Class IV challenges. But compaction stress—heat and force—can trigger recrystallization, undoing the magic.

See more on TaBlitz here

Bringing QbD and DoE into the Mix

This is where Quality by Design (QbD) really earns its keep. You’re not just reacting to problems; you’re mapping critical material attributes early—flow, compressibility, cohesion—and linking them to tablet quality targets like strength and dissolution.

Design of Experiments (DoE) helps explore interactions, but broad ranges waste time on dead ends. What if you could narrow the field first?

That’s the beauty of tools like TaBlitz. As a formulator’s sidekick, it takes your micromeritic data and predicts compaction behavior: tensile strength at real speeds, ejection forces, strain-rate effects. Under QbD, it helps sketch your design space upfront—safe lubricant windows, viable excipient ratios—so your DoE zeros in on winners faster, with less material and fewer runs.

A Smoother Path Forward

For Class III, focus on permeability enhancers without killing rapid disintegration. For Class IV, chase both solubility and absorption while keeping the matrix tablet-friendly.

The takeaway? Formulation and tableting aren’t separate steps—they’re partners. With predictive insights guiding your QbD and DoE, those tricky BCS classes feel less like obstacles and more like puzzles you can actually solve.

What challenges have you hit with these techniques? The science is evolving fast, and smarter workflows are making it easier every day.

Source: TaBlitz

See more on TaBlitz here